Christopher Raymond
Stock Analyst at Piper Sandler
(4.10)
# 600
Out of 4,496 analysts
85
Total ratings
61.7%
Success rate
8.4%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,000 → $1,166 | $1,063.60 | +9.63% | 4 | Jul 19, 2024 | |
| BIIB Biogen | Maintains: Overweight | $335 → $313 | $226.40 | +38.25% | 9 | Jul 12, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $190 | $172.32 | +10.26% | 9 | Jul 2, 2024 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $9 → $7 | $2.14 | +227.10% | 2 | Jul 1, 2024 | |
| ARDX Ardelyx | Maintains: Overweight | $15 | $5.51 | +172.23% | 5 | May 24, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $450 → $456 | $491.57 | -7.24% | 5 | May 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $78 → $104 | $114.97 | -9.54% | 2 | May 3, 2024 | |
| ABVX Abivax | Initiates: Overweight | $42 | $12.40 | +238.71% | 1 | Apr 29, 2024 | |
| QTTB Q32 Bio | Initiates: Overweight | $45 | $29.46 | +52.75% | 1 | Apr 2, 2024 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $11 → $21 | $6.15 | +241.46% | 5 | Mar 8, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $115 → $107 | $84.09 | +27.24% | 6 | Feb 23, 2024 | |
| ALVR AlloVir | Downgrades: Neutral | $27 → $1.5 | $0.74 | +101.42% | 2 | Dec 22, 2023 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Overweight | $29 → $36 | $35.98 | +0.06% | 5 | Nov 15, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $7 → $5 | $0.89 | +461.80% | 3 | Nov 3, 2023 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $130 | $42.55 | +205.52% | 4 | Oct 25, 2023 | |
| IOBT IO Biotech | Initiates: Overweight | $10 | $1.58 | +532.91% | 1 | Sep 28, 2023 | |
| COGT Cogent Biosciences | Maintains: Overweight | $22 | $8.61 | +155.52% | 1 | Jun 12, 2023 | |
| AKBA Akebia Therapeutics | Upgrades: Overweight | $2 → $4 | $1.35 | +196.30% | 3 | May 31, 2023 | |
| MGTX MeiraGTx Holdings | Maintains: Overweight | $26 → $25 | $4.42 | +465.61% | 1 | May 12, 2023 | |
| AMGN Amgen | Maintains: Overweight | $293 → $288 | $331.29 | -13.07% | 9 | Apr 28, 2023 | |
| AGIO Agios Pharmaceuticals | Initiates: Overweight | $41 | $46.61 | -12.04% | 1 | Feb 3, 2023 | |
| ONON On Holding AG | Initiates: Overweight | $28 | $40.06 | -30.10% | 1 | Jul 26, 2022 | |
| NUVL Nuvalent | Initiates: Overweight | n/a | $78.96 | - | 1 | Aug 23, 2021 | |
| SLDB Solid Biosciences | Initiates: Neutral | n/a | $8.22 | - | 1 | Jul 12, 2021 | |
| ACRS Aclaris Therapeutics | Initiates: Overweight | n/a | $1.32 | - | 1 | Jun 15, 2021 | |
| INO Inovio Pharmaceuticals | Downgrades: Neutral | $96 | $10.07 | +853.33% | 2 | Mar 13, 2020 |
Regeneron Pharmaceuticals
Jul 19, 2024
Maintains: Overweight
Price Target: $1,000 → $1,166
Current: $1,063.60
Upside: +9.63%
Biogen
Jul 12, 2024
Maintains: Overweight
Price Target: $335 → $313
Current: $226.40
Upside: +38.25%
AbbVie
Jul 2, 2024
Maintains: Overweight
Price Target: $190
Current: $172.32
Upside: +10.26%
Taysha Gene Therapies
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.14
Upside: +227.10%
Ardelyx
May 24, 2024
Maintains: Overweight
Price Target: $15
Current: $5.51
Upside: +172.23%
Vertex Pharmaceuticals
May 7, 2024
Maintains: Overweight
Price Target: $450 → $456
Current: $491.57
Upside: -7.24%
Blueprint Medicines
May 3, 2024
Maintains: Neutral
Price Target: $78 → $104
Current: $114.97
Upside: -9.54%
Abivax
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $12.40
Upside: +238.71%
Q32 Bio
Apr 2, 2024
Initiates: Overweight
Price Target: $45
Current: $29.46
Upside: +52.75%
ALX Oncology Holdings
Mar 8, 2024
Maintains: Overweight
Price Target: $11 → $21
Current: $6.15
Upside: +241.46%
BioMarin Pharmaceutical
Feb 23, 2024
Maintains: Overweight
Price Target: $115 → $107
Current: $84.09
Upside: +27.24%
AlloVir
Dec 22, 2023
Downgrades: Neutral
Price Target: $27 → $1.5
Current: $0.74
Upside: +101.42%
Biohaven Pharmaceutical Holding Company
Nov 15, 2023
Maintains: Overweight
Price Target: $29 → $36
Current: $35.98
Upside: +0.06%
Karyopharm Therapeutics
Nov 3, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $0.89
Upside: +461.80%
Ultragenyx Pharmaceutical
Oct 25, 2023
Maintains: Overweight
Price Target: $135 → $130
Current: $42.55
Upside: +205.52%
IO Biotech
Sep 28, 2023
Initiates: Overweight
Price Target: $10
Current: $1.58
Upside: +532.91%
Cogent Biosciences
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $8.61
Upside: +155.52%
Akebia Therapeutics
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.35
Upside: +196.30%
MeiraGTx Holdings
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $4.42
Upside: +465.61%
Amgen
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $331.29
Upside: -13.07%
Agios Pharmaceuticals
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $46.61
Upside: -12.04%
On Holding AG
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $40.06
Upside: -30.10%
Nuvalent
Aug 23, 2021
Initiates: Overweight
Price Target: n/a
Current: $78.96
Upside: -
Solid Biosciences
Jul 12, 2021
Initiates: Neutral
Price Target: n/a
Current: $8.22
Upside: -
Aclaris Therapeutics
Jun 15, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.32
Upside: -
Inovio Pharmaceuticals
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $10.07
Upside: +853.33%